Group 1 - The new consumption concept stocks in the Hong Kong market showed mixed performance in the afternoon session [1] - Bluetec (00325.HK) surged over 24%, indicating strong investor interest [1] - Mixue Group (02097.HK) rose nearly 7%, reflecting positive market sentiment [1] Group 2 - Gu Ming (01364.HK) increased by over 5.5%, suggesting a stable growth trend [1] - Giant Bio (02367.HK) saw a rise of over 4%, indicating resilience in its stock performance [1] - Lao Pu Gold (06181.HK) declined nearly 3%, showing some weakness in the market [1] Group 3 - Hu Shang Ayi (02589.HK) fell by 1.3%, indicating a slight downturn in its stock [1]

Core Viewpoint - The ongoing public dispute between two major players in the beauty industry, Huaxi Biological and Juzhi Biological, has escalated into a fierce battle over allegations of fraud and market manipulation, significantly impacting their market positions and stock prices [1][4][34]. Group 1: Background and Timeline - The conflict began on May 17 when Huaxi Biological publicly criticized several brokerage reports that favored Juzhi Biological's products, suggesting they misled the market [5][6]. - On May 24, beauty influencer Hao Yu accused Juzhi Biological of fraud regarding its "collagen stick" product, claiming the actual collagen content was only 0.0177%, far below the labeled 0.1% [16][17]. - Following these allegations, Juzhi Biological issued a rebuttal, presenting an internal quality inspection report to counter the fraud claims [18][19]. Group 2: Market Impact - Since the dispute began, Huaxi Biological's stock price has increased by approximately 6.8%, while Juzhi Biological's stock has seen a cumulative decline of 25.20%, resulting in a market value loss of over 16 billion HKD [34]. - The consumer market has also reacted, with Juzhi Biological's product ranking dropping significantly on e-commerce platforms, indicating a shift in consumer perception [36]. Group 3: Industry Dynamics - The conflict highlights a broader competition between two factions in the beauty industry: the hyaluronic acid camp represented by Huaxi Biological and the recombinant collagen camp led by Juzhi Biological [39]. - The rise of recombinant collagen products has been attributed to a lack of standardized regulations and testing methods, allowing companies like Juzhi Biological to capitalize on marketing without stringent scientific backing [41]. - In contrast, Huaxi Biological has faced significant challenges, with its market value plummeting from 140 billion to 26.1 billion, while Juzhi Biological's market capitalization has surged by 230% since its IPO [37].

近日，淡出直播行业许久的薇娅又有了"复出"的迹象。有网友在社交平台发文称，一个名为"谦寻超级会员"的微信小程序悄然上线， 背后有着薇娅夫妇的身影，薇娅本人更是在视频中做出镜模特。 薇娅隐秘复出？ 据新黄河报道，5月22日凌晨，董海峰先是在其抖音账号发布纪念薇娅直播九周年的温情视频，引发粉丝怀旧情绪。随后，他在一 条"没有薇娅……"的高赞评论下，首次透露了名为"谦寻超级会员"的小程序，并直接引导粉丝"先关注、注册"。 后续发布的视频中， 薇娅本人亲自出镜担当服装模特，董海峰则将小程序称为粉丝的"秘密基地"。 不过6月8日，董海锋的抖音账号中， 上述有关薇娅的视频目前已经搜索不到。 据红星新闻报道，薇娅背后的MCN公司即"谦寻（杭州）控股有限责任公司"，董海锋推荐的小程序名字中也有"谦寻"两字。小程序页 面类似于一个私域商城，销售产品类别显示有美妆、食品、日用百货和穿搭等。 "谦寻超级会员"与"薇娅惊喜社"主体公司相同 据新黄河报道， "谦寻超级会员"小程序客服的企业微信主体为杭州澜度科技有限公司，2024年公众号"薇娅惊喜社"迁移至"哆啦的魔 法棒", 哆啦的魔法棒的认证主体同样是杭州澜度科技有限公司。 如今， ...

巨子生物(02367.HK)：公司控股股东Juzi Holding计划自本公告日期起三至六个月内增持本公司股份， 增持金额不低于港币2亿元。 ...

Core Insights - The company plans to acquire a 65% stake in Xing Si Yu Investment from Five Star Holdings, making it a subsidiary, and simultaneously acquire 100% of Si Yu Industrial for 1.65 billion yuan [1] - Si Yu Industrial, established in July 2014, is a leading player in the hair health sector, focusing on personal care products and services, with projected revenue of 723 million yuan and net profit of 181 million yuan in 2024 [2] - The hair care market in China has grown from 43.23 billion yuan in 2020 to 57.09 billion yuan in 2023, with a compound annual growth rate of 9.7%, indicating significant market potential [2] - Si Yu Industrial is implementing a "Technology Hair Care 3.0" strategy, transitioning towards a technology-driven and professional approach in hair care solutions [2] - The company has over 160 specialized hair and scalp products and holds 48 patents, including 7 invention patents, showcasing its strong innovation capabilities [3] - Si Yu Industrial operates an integrated business model with 2,503 stores, including 176 direct-operated and 2,327 franchised stores, and has over 2 million members [3] - The acquisition will enhance the company's service offerings and strengthen its position in the local lifestyle and family service sectors [3] - The company aims to leverage a global differentiated supply chain and local parenting services, with a focus on member engagement and digital upgrades [4] - Revenue projections for 2025-2027 are 10.7 billion yuan, 12.68 billion yuan, and 14.61 billion yuan, with net profits of 300 million yuan, 410 million yuan, and 540 million yuan respectively [4]

证券研究报告 孩子王 (301078 CH) 丝域实业 100%股权的转让价格为 16.5 亿元，分为 6.6、9.9 亿元两笔支付， 其中，孩子王拟将原用于"门店升级改造项目"的 4.29 亿元可转债募集资 金用于此次收购，并由江苏星丝域向金融机构贷款以支付第二笔款项。丝域 实业原创始人陈英燕、王德友积极参与此次并购，我们认为有助于强化产业 协同和资源整合，也展示了其对于丝域实业未来发展的信心。收购后，孩子 王及丝域实业将在会员运营、场景布局、渠道共享、产业协同等方面发挥协 同效应，强化公司在本地生活和新家庭服务领域的领先优势，推动公司向中 国新家庭全渠道服务商加速迈进。 盈利预测与估值 此次交易已经过公司董事会审议通过，考虑到还需通过公司股东会审议，故 我们暂时维持盈利预测不变，预计 2025-2027 年归母净利润 3.37/4.75/6.88 亿元。参考可比公司 2026 年 iFind 一致预期 PE 均值 36 倍，考虑到公司围 绕新家庭零售场景不断强化产业链竞争优势，且积极发展 AI 业务、提升数 智化能力，维持目标价 19 元，对应公司 2026 年 50 倍目标 PE。 | 华泰研究 | | ...

Summary of Conference Call Records Industry Overview - The conference call discusses the new consumption sector, focusing on industries such as daily chemicals, personal care, and health products, which are entering a product upgrade cycle with strong sustainability [1][5]. Key Points and Arguments - **New Consumption Drivers**: The current wave of new consumption is driven by product renewal and innovation rather than relying on traffic purchases. Companies need stronger content marketing capabilities and market insight, making innovation a key competitive factor [1][3]. - **Market Characteristics**: The new consumption market is characterized by a shift from functional needs to emotional value needs, with traditional products being revamped to meet these new demands [4][5]. - **Market Volatility**: Recent fluctuations in the new consumption market are considered normal after significant growth phases. The current cycle is less elastic compared to the previous one, with a focus on replacing and upgrading existing products [3][6]. - **Valuation Metrics**: Most new consumption companies have a PEG ratio between 1 and 1.3, indicating they may be slightly overvalued. However, there is potential for valuation recovery as risk appetite increases [7]. - **Impact of Shareholder Actions**: Shareholder sell-offs do not necessarily indicate a peak in stock prices, as they can be influenced by various factors. As long as risk appetite remains stable and innovation cycles continue, the new consumption sector still has growth potential [8]. Industry Trends - **Sustained Innovation**: Industries such as beauty, snacks, gold and jewelry, trendy toys, and tea drinks are expected to maintain high-frequency innovation, while stable categories like daily chemicals and personal care are entering a more robust upgrade cycle [5][9]. - **Investment Recommendations**: Traditional growth companies in sectors like beverages and beer are recommended for investment due to their lower valuations and higher cost-effectiveness. Emerging growth companies like Ruoyuchen and Jingbo Biological are also highlighted for their innovative capabilities [2][10]. Potential Investment Opportunities - **Specific Companies**: In the cosmetics sector, companies like Juzhi Biological and Runben Co. are noted for their stability and growth potential. In the food and beverage sector, companies such as Yanjinpuzi and Weilong Food are performing well, with others like Bailong Chuangyuan and Three Squirrels also identified as promising investments [11]. Conclusion - The new consumption sector may experience a consolidation phase, but this does not imply an end to growth. Traditional growth companies may outperform during this period, suggesting a need for dynamic adjustments in investment strategies to optimize returns [12].

Summary of Conference Call Records Industry Overview - The overall consumer market in China is weak, with significant deflationary pressures. The 618 promotional event highlighted insufficient demand, and the growth rate for the Dragon Boat Festival did not show significant improvement, with per capita consumption down approximately 12% compared to pre-pandemic levels [1][4]. Key Insights and Arguments - **Stock Selection Strategy**: The strategy focuses on companies in distress reversal, emerging high-growth sectors, and those with reasonable valuations and excellent operations. Recommended stocks include dairy companies (Mengniu, Yili), jewelry (Chow Tai Fook), emerging consumption (Pop Mart, Giant Bio), sports brands (Yum China, Anta), and Bosideng [1][6]. - **Food Sector Performance**: The snack food category has seen significant revenue growth, benefiting from new channels and health awareness. For instance, Wei Long's konjac products have exceeded expectations [1][7]. - **Sports Sector Sales**: Sales in the sports sector were affected in April but improved in May due to promotional activities, although discounts deepened. Brands like Li Ning and Anta increased discounts, leading to higher inventory levels and decreased sales [1][11]. - **Lululemon's Growth**: Lululemon's China operations maintained over 30% growth, while high-end niche brands are growing rapidly, reflecting changes in consumer lifestyles [1][12]. - **Airline Industry Outlook**: The airline industry is expected to be one of the first to emerge from the deflation trap due to supply-side constraints and improved pricing power. The industry has seen a 5% year-on-year increase in ticket prices, indicating effective price control [1][20]. Additional Important Content - **Consumer Behavior**: The disparity between new and traditional consumption sectors is evident, with new consumption stocks in Hong Kong rising nearly 150% year-to-date, while traditional consumer stocks have only increased about 9% [2]. - **Market Dynamics**: The overall consumer market remains relatively weak, with no significant improvement observed. The increase in discount rates across various sectors indicates a need for price incentives to stimulate demand [3]. - **Future Expectations**: The next few months may see continued imbalance in the consumer market, with traditional sectors like liquor and beer remaining weak, while beverages and home appliances may perform better due to seasonal effects and government subsidies [5]. - **Jewelry Sector Trends**: The jewelry sector, particularly brands like Chow Tai Fook, is focusing on traditional gold craftsmanship, which has led to improved profit margins and sales performance [17]. - **Export Challenges**: Export companies, especially in textiles and footwear, face high uncertainty and volatility due to tariff fluctuations and low order visibility, which may impact overall economic conditions [24][25]. This summary encapsulates the key points from the conference call records, highlighting the current state of various sectors within the consumer market and the strategic recommendations for investment.

长江商报消息 ●长江商报记者 汪静 "成分之争"的风波演变成两大医美巨头间的攻防战，华熙生物（688363.SH）与巨子生物（02367.HK） 之争逐渐白热化。在这背后，"玻尿酸女王"赵燕的焦虑已跃然纸上。 同处医美行业，华熙生物与巨子生物的核心产品重组胶原蛋白与玻尿酸均为具有填充、修复功能的生物 材料。过去，凭借着玻尿酸这一明星成分，华熙生物赢得了业绩与股价的双丰收，也将创始人赵燕送上 了山东女首富的宝座。 随着重组胶原蛋白等新型成分的崛起，华熙生物遭到了上市以来最严峻的挑战——2024年营收同比下滑 11.61%至53.71亿元，净利润骤降70.59%至1.74亿元，核心业务板块收入锐减32.68%。而2024年，医美 新贵巨子生物的营收约55.39亿元，净利润约20.62亿元，双双大幅增长。 "我们正在经历的不是市场周期的简单波动，而是一场关乎企业生存逻辑的深刻变革。"在华熙生物2024 年财报发布后的董事会上，赵燕的发言掷地有声。 赵燕出生于1966年，毕业于华东师范大学生物系，毕业后曾留校担任助教。1988年，海南建省的浪潮 中，赵燕感到机遇来临，于是辞去教职，与其他三名想要创业的大学老师凑了50 ...

Investment Rating - The report maintains an "Outperform" rating for the company [6]. Core Insights - The company plans to acquire a 65% stake in Siyi, which will create synergies with its existing business [6]. - The acquisition price is set at 1.65 billion yuan, corresponding to a PE ratio of approximately 9 times for 2024 [6]. - The hair care industry shows significant growth potential, with the market size expected to reach 81.25 billion yuan by 2028, growing at a CAGR of 7.3% from 2023 to 2028 [6]. - The acquisition is expected to enhance the company's profitability, with revised net profit forecasts for 2025-2027 being 400 million, 600 million, and 796 million yuan, respectively, reflecting year-on-year growth rates of 122%, 50%, and 32% [6]. Financial Data and Profit Forecast - Total revenue projections for the company are as follows: 9,337 million yuan in 2024, 11,608 million yuan in 2025, 12,614 million yuan in 2026, and 13,989 million yuan in 2027, with respective growth rates of 6.7%, 24.3%, 8.7%, and 10.9% [5]. - The company's net profit is forecasted to be 181 million yuan in 2024, 402 million yuan in 2025, 602 million yuan in 2026, and 796 million yuan in 2027, with growth rates of 72.4%, 121.8%, 49.8%, and 32.1% [5]. - The company's ROE is expected to improve from 4.6% in 2024 to 14.4% in 2027 [5].